Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study - Concepedia

Concepedia

Publication | Closed Access

Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

106

Citations

15

References

2016

Year

Benoît Trottier, Jordan E. Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin Koteff, Brian Wynne, Judy Hopking, Catherine Granier,

Antiviral Therapy

Abstract

Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression.

References

	Year	Citations

Page 1